ACUTE LYMPHOCYTIC LEUKEMIA, ADULT
Abatacept, Cyclosprine, Tacrolimus, and Methotrexate in Preventing Graft-versus-Host Disease in Patients With High-Risk Leukemia Undergoing Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Supportive care
Age: 6 and over
Trial IDs: 2692.00, NCI-2016-00220, PBMTC PROTOCOL GVH 1201, NCT01743131
CXCR4 Antagonist BL-8040 in Mobilizing Stem Cells for Donor Transplant in Healthy Donors and Patients with Advanced Hematological Malignancies
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: 2016002037, NCI-2016-00197, NCT02639559
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 and over
Trial IDs: ADCT-402-102, NCI-2016-00226, NCT02669264
BREAST CANCER
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CP-MGAH22-04, NCI-2016-00295, NCT02492711
Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-119, NCI-2016-00327, 2015-001020-27, NCT02555657
Phase Ib/II trial using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer with CNS Metastasis
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TRIO-US B09, NCI-2013-00082, 12-001358-CR-00003, CRAD001JUS182T, NCT01783756
Durvalumab and Combination Chemotherapy in Treating Patients With Stage I-III Triple Negative Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 1409014537, NCI-2016-00070, ESR-14-10265, NCT02489448
Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer (KEYNOTE-162)
Status: Not yet active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 3000-PN162-01-001, NCI-2016-00219, NCT02657889
COLON CANCER
Pilot Study to Determine Biodistribution of MM-398 and Feasibility of Ferumoxytol as a Tumor Imaging Agent
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Age: 18 and over
Trial IDs: MM-398-01-01-02, NCI-2016-00161, NCT01770353
Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CPI-444-001, NCI-2016-00227, NCT02655822
METASTATIC CANCER
Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older
Status: Active
Phase: Phase IV
Type: Treatment
Age: 70 and over
Trial IDs: 1200.209, NCI-2016-00277, NCT02514174
A Study of JNJ-56021927 (ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With Low-Volume mHSPC
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CR107614, NCI-2016-00191, 2015-000735-32, 56021927PCR3002, NCT02489318
Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHP-OCM-301, NCI-2016-00242, NCT02678572
Phase Ib/II trial using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TRIO-US B09, NCI-2013-00082, 12-001358-CR-00003, CRAD001JUS182T, NCT01783756
Sipuleucel-T With or Without Radium Ra 223 Dichloride in Treating Patients With Asymptomatic or Minimally Symptomatic Bone-Metastatic Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J1522, NCI-2016-00266, NCT02463799
Palliative Radiation Therapy in Reducing Pain in Patients With Bone Metastasis
Status: Not yet active
Phase: Phase II
Type: Supportive care
Age: Not specified
Trial IDs: CCCWFU 01416, NCI-2016-00204, NCT02699697
Multicenter Study of Cryoablation for Palliation of Painful Bone Metastases
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: CGC15-BNE098, NCI-2016-00249, NCT02511678
NON-HODGKIN LYMPHOMA
Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: FF-10502-01, NCI-2016-00184, NCT02661542
Ixazomib Citrate after Stem Cell Transplant in Treating Patients With Mantel Cell Lymphoma in Remission
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Winship2839-15, NCI-2015-01943, IRB00076016, Winship2839-15 (X16058), X16058, NCT02632396
A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CA209-436, NCI-2016-00313, 2015-003286-28, NCT02581631
Abatacept, Cyclosprine, Tacrolimus, and Methotrexate in Preventing Graft-versus-Host Disease in Patients With High-Risk Leukemia Undergoing Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Supportive care
Age: 6 and over
Trial IDs: 2692.00, NCI-2016-00220, PBMTC PROTOCOL GVH 1201, NCT01743131
Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: KO-TIP-002, NCI-2016-00235, NCT02464228
Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-196, NCI-2016-00065, NCT02633137